Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label, Phase II Study of Trastuzumab in Combination With Lapatinib (Cohort A) or Pertuzumab in Combination With Trastuzumab-emtansine (Cohort B) in Patients With HER2-positive Metastatic Colorectal Cancer: the HERACLES (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification)Trial

Next Previous
X
Search
Trial Profile

Open-Label, Phase II Study of Trastuzumab in Combination With Lapatinib (Cohort A) or Pertuzumab in Combination With Trastuzumab-emtansine (Cohort B) in Patients With HER2-positive Metastatic Colorectal Cancer: the HERACLES (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification)Trial

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lapatinib (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
  • Indications Adenocarcinoma; Colon cancer; Rectal cancer
  • Focus Therapeutic Use
  • Acronyms HERACLES

    • Most Recent Events

    • 21 Sep 2020 Results (n=92) of an analysis from HERACLES clinical program and other clinical trials assessing prevalence, timing of onset, and management of CNS recurrences in largest cohort of Colorectal cancer treated with anti-HER2 therapies at Niguarda Cancer Center presented at the 45th European Society for Medical Oncology Congress
    • 04 Jun 2019 Results assessing use CT texture analysis (CTTA) to identify imaging biomarkers of HER2+ mCRC able to predict lesion response to therapy published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
    • 29 Oct 2018 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top